Sanatorio Güemes, Buenos Aires, AR.
Pharmacology Department, School of Medicine, University of Buenos Aires, AR.
Glob Heart. 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
As the global COVID-19 pandemic advances, it increasingly impacts those vulnerable populations who already bear a heavy burden of neglected tropical disease. Chagas disease (CD), a neglected parasitic infection, is of particular concern because of its potential to cause cardiac, gastrointestinal, and other complications which could increase susceptibility to COVID-19. The over one million people worldwide with chronic Chagas cardiomyopathy require special consideration because of COVID-19's potential impact on the heart, yet the pandemic also affects treatment provision to people with acute or chronic indeterminate CD. In this document, a follow-up to the WHF-IASC Roadmap on CD, we assess the implications of coinfection with SARS-CoV-2 and , the etiological agent of CD. Based on the limited evidence available, we provide preliminary guidance for testing, treatment, and management of patients affected by both diseases, while highlighting emerging healthcare access challenges and future research needs.
随着全球 COVID-19 大流行的进展,它越来越多地影响到那些已经承担着被忽视的热带病沉重负担的弱势群体。恰加斯病(CD)是一种被忽视的寄生虫感染,尤其令人关注,因为它有可能导致心脏、胃肠道和其他并发症,从而增加对 COVID-19 的易感性。全世界有超过 100 万患有慢性恰加斯心肌病的人需要特别考虑,因为 COVID-19 有可能对心脏产生影响,但大流行也影响到对急性或慢性不定型 CD 患者的治疗提供。在这份文件中,我们对恰加斯病 WHF-IASC 路线图的后续行动进行了评估,评估了与 SARS-CoV-2 合并感染的影响,恰加斯病的病原体。根据现有有限的证据,我们为同时感染这两种疾病的患者的检测、治疗和管理提供了初步指导,同时强调了新出现的医疗保健获取挑战和未来的研究需求。